| Identification | Back Directory | [Name]
AP-III-a4 | [CAS]
1177827-73-4 | [Synonyms]
CS-1077
ENOBLOCK
AP-III-a4
ENOblock (AP-III-a4)
ENOBLOCK HYDROCHLORIDE
AP-III-a4(ENOblock), >98%
N-[2-[2-(2-Aminoethoxy)ethoxy]ethyl]-4-[[4-[(cyclohexylmethyl)amino]-6-[[(4-fluorophenyl)methyl]amino]-1,3,5-triazin-2-yl]amino]benzeneacetamide
Benzeneacetamide, N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-4-[[4-[(cyclohexylmethyl)amino]-6-[[(4-fluorophenyl)methyl]amino]-1,3,5-triazin-2-yl]amino]-
AP-III-A4 Benzeneacetamide, N-[2-[2-(2-aminoethoxy)ethoxy]ethyl]-4-[[4-[(cyclohexylmethyl)amino]-6-[[(4-fluorophenyl)methyl]amino]-1,3,5-triazin-2-yl]amino]- | [Molecular Formula]
C31H43FN8O3 | [MDL Number]
MFCD28009373 | [MOL File]
1177827-73-4.mol | [Molecular Weight]
594.72 |
| Chemical Properties | Back Directory | [density ]
1.250±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C(protect from light) | [solubility ]
Soluble in DMSO | [form ]
Powder | [pka]
15.25±0.46(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
AP-III-a4 (ENOblock) is a nonsubstrate analogue enolase inhibitor with an IC50 of 0.576 uM. AP-III-a4 can be used for the research of cancer and diabetic[1]. | [in vivo]
AP-III-a4 (ENOblock) (10 μM; 96 h) inhibits cancer cell metastasis and suppresses the gluconeogenesis regulator PEPCK in zebrafish[1]. | Animal Model: | The zebrafish cancer cell HCT116 xenograft model[1] | | Dosage: | 10 μM | | Administration: | 96 h | | Result: | Reduced cancer cell dissemination. Inhibited PEPCK expression and induced glucose uptake. Inhibited adipogenesis and foam cell formation. |
| [References]
[1] Da-Woon Jung, et al. A Unique Small Molecule Inhibitor of Enolase Clarifies Its Role in Fundamental Biological Processes.ACS Chem. Biol., 2013, 8 (6), pp 1271–1282 DOI:10.1021/cb300687k |
|
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|